Holen Sie sich die Stockscreener-App
15.52
2.04%
0.31
Schlusskurs vom Vortag:
$15.21
Offen:
$15.27
24-Stunden-Volumen:
176.98K
Relative Volume:
0.54
Marktkapitalisierung:
$560.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.34%
1M Leistung:
-13.34%
6M Leistung:
-33.22%
1J Leistung:
+0.00%
1-Tages-Spanne:
$15.15
$15.89
1-Wochen-Bereich:
$15.15
$16.04
52-Wochen-Spanne:
$10.01
$32.75
Ceribell Inc Stock (CBLL) Company Profile
Firmenname
Ceribell Inc
Sektor
Branche
Telefon
(800) 436-0826
Adresse
360 N. PASTORIA AVENUE, SUNNYVALE
Vergleichen Sie CBLL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
15.52 | 568.53M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-24 | Eingeleitet | BTIG Research | Buy |
| 2025-04-04 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-11-05 | Eingeleitet | BofA Securities | Buy |
| 2024-11-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Ceribell Inc Aktie (CBLL) Neueste Nachrichten
Is CeriBell Inc. a good long term investmentSuperior stock selection - jammulinksnews.com
What drives CeriBell Inc. stock priceHigh-profit capital plays - jammulinksnews.com
CeriBell Inc. Stock Analysis and ForecastSuperior stock growth - jammulinksnews.com
Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025 - The Manila Times
What analysts say about CeriBell Inc. stockExceptional gains - printweek.in
How CeriBell Inc. stock performs during market volatilityReturn Optimized Trade Insights - Newser
Brokerages Set CeriBell, Inc. (NASDAQ:CBLL) Price Target at $32.14 - Defense World
What makes CeriBell Inc. stock price move sharplyFast Gains With Reduced Risk - Newser
Why CeriBell Inc. stock attracts strong analyst attentionWeekly Double Return List - Newser
CeriBell shares drop 38% following InvestingPro’s overvaluation warning By Investing.com - Investing.com South Africa
Ceribell sues Natus Medical for patent infringement - MSN
Ceribell, Inc.’s Strategic Positioning and Patent Strength Justify Buy Rating - TipRanks
Ceribell (CBLL) CEO Chao sells $442,500 in stock By Investing.com - Investing.com South Africa
Ceribell (CBLL) CEO Chao sells $442,500 in stock - Investing.com
Ceribell files patent infringement complaints against Natus Medical By Investing.com - Investing.com South Africa
Ceribell's IP Offense: How Legal Aggression Could Spark a Neurotech Breakout - AInvest
Ceribell files patent infringement complaints against Natus Medical - Investing.com Australia
Ceribell's Legal Offense and Pediatric Breakthrough: A Strategic Double Play for Market Dominance - AInvest
Ceribell Files Patent Infringement Complaints Against Natus - TipRanks
CeriBell Files Patent Infringement Complaints Against Natus Medical - MarketScreener
Ceribell sues Natus Medical for patent infringement (CBLL) - Seeking Alpha
Ceribell files complaints against Natus Medical, alleges patent infringement - TipRanks
CeriBell, Inc. Files Patent Infringement Complaints Against Natus Medical Incorporated - Nasdaq
Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware - GlobeNewswire
Ceribell Hits Competitor With Patent Lawsuit Over Wearable EEG - Bloomberg Law News
Finanzdaten der Ceribell Inc-Aktie (CBLL)
Es liegen keine Finanzdaten für Ceribell Inc (CBLL) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):